MDM2 and medulloblastoma: A recent study by Gwynne et al. [172] has shown that, in medulloblastoma, MYC (a downstream target of the MDM2/p53 pathway [138]) is stabilised by O-GlcNAcylation and that medulloblastoma cells were sensitive to inhibition of the de novo pyrimidine synthesis.